BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gowda C, Lott S, Grigorian M, Carbonari DM, Saine ME, Trooskin S, Roy JA, Kostman JR, Urick P, Lo Re V 3rd. Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study. Open Forum Infect Dis 2018;5:ofy076. [PMID: 29977955 DOI: 10.1093/ofid/ofy076] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Waters P, Broder T. Rationing Care: Barriers to Direct-Acting Antiviral Treatment in Medicaid Treatment Criteria. Clin Liver Dis (Hoboken) 2018;12:122-4. [PMID: 30988926 DOI: 10.1002/cld.751] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
2 Mera J, Reilley B, Leston J, Stephens D. In a Critical State: Ongoing Barriers to Treatment for Hepatitis C Virus (HCV). Am J Med 2019;132:547-9. [PMID: 30476467 DOI: 10.1016/j.amjmed.2018.10.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
3 Erman A, Wong WWL, Feld JJ, Grootendorst P, Krahn MD. The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach. Liver Int 2020;40:51-9. [PMID: 31509639 DOI: 10.1111/liv.14247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Gupta G, Yakubu I, Zhang Y, Kimball P, Kang L, Mitchell K, Ijioma S, Carroll N, Patterson J, Shinbashi M, Kumar D, Moinuddin I, Kamal L, King A, Bhati C, Levy M, Cotterell A, Khan A, Sharma A, Sterling R. Outcomes of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants. Am J Transplant 2021. [PMID: 34212479 DOI: 10.1111/ajt.16747] [Reference Citation Analysis]
5 Metsch LR, Feaster DJ, Gooden LK, Masson C, Perlman DC, Jain MK, Matheson T, Nelson CM, Jacobs P, Tross S, Haynes L, Lucas GM, Colasanti JA, Rodriguez A, Drainoni ML, Osorio G, Nijhawan AE, Jacobson JM, Sullivan M, Metzger D, Vergara-Rodriguez P, Lubelchek R, Duan R, Batycki JN, Matthews AG, Munoz F, Jelstrom E, Mandler R, Del Rio C. Care Facilitation Advances Movement Along the Hepatitis C Care Continuum for Persons With Human Immunodeficiency Virus, Hepatitis C, and Substance Use: A Randomized Clinical Trial (CTN-0064). Open Forum Infect Dis 2021;8:ofab334. [PMID: 34377726 DOI: 10.1093/ofid/ofab334] [Reference Citation Analysis]
6 Saeed S, Strumpf E, Moodie EEM, Wong L, Cox J, Walmsley S, Tyndall M, Cooper C, Conway B, Hull M, Martel-Laferriere V, Gill J, Wong A, Vachon ML, Klein MB; Canadian Coinfection Cohort Study Investigators. Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus. Clin Infect Dis 2020;71:363-71. [PMID: 31504327 DOI: 10.1093/cid/ciz833] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
7 Rosenberg ES, Rosenthal EM, Hall EW, Barker L, Hofmeister MG, Sullivan PS, Dietz P, Mermin J, Ryerson AB. Prevalence of Hepatitis C Virus Infection in US States and the District of Columbia, 2013 to 2016. JAMA Netw Open. 2018;1:e186371. [PMID: 30646319 DOI: 10.1001/jamanetworkopen.2018.6371] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 21.0] [Reference Citation Analysis]
8 Du P, Wang X, Kong L, Riley T 3rd, Jung J. Changing Urban-Rural Disparities in the Utilization of Direct-Acting Antiviral Agents for Hepatitis C in U.S. Medicare Patients, 2014-2017. Am J Prev Med 2021;60:285-93. [PMID: 33221144 DOI: 10.1016/j.amepre.2020.08.031] [Reference Citation Analysis]
9 Chua JV, Ntem-Mensah A, Abutaleb A, Husson J, Mutumbi L, Lam KW, Ghosh A, Romani S, Poonia B, Lee S, Luz Pascual M, Frumkin LR, Kottilil S. Short-duration treatment with the novel non-nucleoside inhibitor CDI-31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: An open-label study. J Med Virol 2021;93:3752-60. [PMID: 33150966 DOI: 10.1002/jmv.26652] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Spradling PR, Xing J, Rupp LB, Moorman AC, Gordon SC, Lu M, Teshale EH, Boscarino JA, Schmidt MA, Daida YG, Holmberg SD. Low Uptake of Direct-acting Antiviral Therapy Among Hepatitis C Patients With Advanced Liver Disease and Access to Care, 2014-2017. Journal of Clinical Gastroenterology 2021;55:77-83. [DOI: 10.1097/mcg.0000000000001344] [Reference Citation Analysis]
11 Jiang X, Song HJ, Wang W, Henry L, Childs-Kean LM, Re VL 3rd, Park H. The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders. J Manag Care Spec Pharm 2021;27:873-81. [PMID: 34185563 DOI: 10.18553/jmcp.2021.27.7.873] [Reference Citation Analysis]
12 Kapadia SN, Gulick RM. Drug Costs: What Can Infectious Diseases Physicians Do? J Infect Dis 2020;221:681-4. [PMID: 30887031 DOI: 10.1093/infdis/jiz067] [Reference Citation Analysis]
13 Driedger M, Vachon M, Wong A, Conway B, Ramji A, Borgia S, Tam E, Barrett L, Smyth D, Feld J, Lee SS, Cooper C. Direct-acting antiviral treatment uptake and sustained virological response outcomes are not affected by alcohol use: A CANUHC analysis. CanLivJ 2021;4:283-91. [DOI: 10.3138/canlivj-2021-0003] [Reference Citation Analysis]
14 Manne V, Ryan J, Wong J, Vengayil G, Basit SA, Gish RG. Hepatitis C Vaccination: Where We Are and Where We Need to Be. Pathogens 2021;10:1619. [PMID: 34959574 DOI: 10.3390/pathogens10121619] [Reference Citation Analysis]
15 Seaman A, Ronan W, Myers L, Wheelock H, Butler M, Nelson L, E. Williams B, Zaman A. Hepatitis C Treatment Among People Who Use Drugs in an Office-Based Opioid Treatment Program Versus a Syringe Exchange Program: A Real-World Prospective Clinical Trial. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.114781] [Reference Citation Analysis]
16 Liu L, Daftary MN, Alzahrani MS, Ohanele C, Maneno MK. Barriers to the Treatment of Hepatitis C among Predominantly African American Patients Seeking Care in an Urban Teaching Hospital in Washington, D.C. J Natl Med Assoc 2021;113:147-57. [PMID: 32868101 DOI: 10.1016/j.jnma.2020.08.006] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, Dusheiko G, Feld JJ, Gore C, Griswold MG, Hamid S, Hellard ME, Hou J, Howell J, Jia J, Kravchenko N, Lazarus JV, Lemoine M, Lesi OA, Maistat L, McMahon BJ, Razavi H, Roberts T, Simmons B, Sonderup MW, Spearman CW, Taylor BE, Thomas DL, Waked I, Ward JW, Wiktor SZ; Lancet Gastroenterology & Hepatology Commissioners. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4:135-184. [PMID: 30647010 DOI: 10.1016/s2468-1253(18)30270-x] [Cited by in Crossref: 180] [Cited by in F6Publishing: 79] [Article Influence: 90.0] [Reference Citation Analysis]
18 Cipriano LE, Liu S, Shahzada KS, Holodniy M, Goldhaber-Fiebert JD. Economically Efficient Hepatitis C Virus Treatment Prioritization Improves Health Outcomes. Med Decis Making 2018;38:849-65. [PMID: 30132410 DOI: 10.1177/0272989X18792284] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
19 Saeed YA, Phoon A, Bielecki JM, Mitsakakis N, Bremner KE, Abrahamyan L, Pechlivanoglou P, Feld JJ, Krahn M, Wong WW. A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C. Value in Health 2020;23:127-37. [DOI: 10.1016/j.jval.2019.07.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Reau N, Sulkowski MS, Thomas E, Sundaram V, Xu Q, Cheng WH, Marx SE, Hayes OA, Manthena SR, Chirikov V, Dylla DE, Brooks H, Carabino JM, Saab S. Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019. Adv Ther 2021;38:5777-90. [PMID: 34704194 DOI: 10.1007/s12325-021-01928-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Siegler AJ, Komro KA, Wagenaar AC. Law Everywhere: A Causal Framework for Law and Infectious Disease. Public Health Rep 2020;135:25S-31S. [PMID: 32735203 DOI: 10.1177/0033354920912991] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Torabi J, Rocca JP, Ajaimy M, Melvin J, Campbell A, Akalin E, Liriano LE, Azzi Y, Pynadath C, Greenstein SM, Le M, Goldstein DY, Fox AS, Carrero J, Weiss JM, Powell T, Racine AD, Reinus JF, Kinkhabwala MM, Graham JA. Commercial insurance delays direct-acting antiviral treatment for hepatitis C kidney transplantation into uninfected recipients. Transpl Infect Dis. 2021;23:e13449. [PMID: 32810315 DOI: 10.1111/tid.13449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
23 Vo QT, Onofrey S, Church D, Cranston K, DeMaria A, Klevens RM. The Massachusetts Hepatitis C Testing Cascade, 2014-2016. Microbiol Insights 2019;12:1178636119857961. [PMID: 31258329 DOI: 10.1177/1178636119857961] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Spradling PR, Xing J, Rupp LB, Moorman AC, Gordon SC, Lu M, Teshale EH, Boscarino JA, Schmidt MA, Daida YG, Holmberg SD; Chronic Hepatitis Cohort Study (CHeCS) Investigators. Low Uptake of Direct-acting Antiviral Therapy Among Hepatitis C Patients With Advanced Liver Disease and Access to Care, 2014-2017. J Clin Gastroenterol 2021;55:77-83. [PMID: 32250999 DOI: 10.1097/MCG.0000000000001344] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
25 Rosenthal ES, Silk R, Mathur P, Gross C, Eyasu R, Nussdorf L, Hill K, Brokus C, D'Amore A, Sidique N, Bijole P, Jones M, Kier R, McCullough D, Sternberg D, Stafford K, Sun J, Masur H, Kottilil S, Kattakuzhy S. Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs. Clin Infect Dis 2020;71:1715-22. [PMID: 32009165 DOI: 10.1093/cid/ciaa105] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 20.0] [Reference Citation Analysis]
26 Kapadia SN, Johnson P, Marks KM, Schackman BR, Bao Y. Hepatitis C Treatment by Nonspecialist Providers in the Direct-acting Antiviral Era. Med Care 2021;59:795-800. [PMID: 34081676 DOI: 10.1097/MLR.0000000000001573] [Reference Citation Analysis]
27 Sulkowski M, Luetkemeyer AF, Wyles DL, Martorell C, Muir A, Weisberg I, Gordon SC, McLain R, Huhn G. Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherence. Aliment Pharmacol Ther 2020;51:1384-96. [PMID: 32352586 DOI: 10.1111/apt.15707] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 Popping S, Hullegie SJ, Boerekamps A, Rijnders BJA, de Knegt RJ, Rockstroh JK, Verbon A, Boucher CAB, Nichols BE, van de Vijver DAMC. Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men. PLoS One 2019;14:e0210179. [PMID: 30629662 DOI: 10.1371/journal.pone.0210179] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
29 Saine ME, Szymczak JE, Moore TM, Bamford LP, Barg FK, Forde KA, Schnittker J, Holmes JH, Mitra N, Lo Re V 3rd. The impact of disease-related knowledge on perceptions of stigma among patients with Hepatitis C Virus (HCV) infection. PLoS One 2021;16:e0258143. [PMID: 34610030 DOI: 10.1371/journal.pone.0258143] [Reference Citation Analysis]
30 Ho TY, Liu S, Zabinsky ZB. A Multi-Fidelity Rollout Algorithm for Dynamic Resource Allocation in Population Disease Management. Health Care Manag Sci 2019;22:727-55. [PMID: 30194509 DOI: 10.1007/s10729-018-9454-6] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Stewart ZA, Stern J, Ali NM, Kalia HS, Khalil K, Jonchhe S, Weldon EP, Dieter RA, Lewis TC, Funches N, Crosby S, Seow M, Berger JC, Dagher NN, Gelb BE, Watkins AC, Moazami N, Smith DE, Kon ZN, Chang SH, Reyentovich A, Angel LF, Montgomery RA, Lonze BE. Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections. Transplant Direct 2021;7:e762. [PMID: 34514117 DOI: 10.1097/TXD.0000000000001222] [Reference Citation Analysis]
32 Gupta G, Yakubu I, Bhati CS, Zhang Y, Kang L, Patterson JA, Andrews-Joseph A, Alam A, Ferreira-Gonzalez A, Kumar D, Moinuddin IK, Kamal L, King AL, Levy M, Sharma A, Cotterell A, Reichman TW, Khan A, Kimball P, Stiltner R, Baldecchi M, Brigle N, Gehr T, Sterling RK. Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients. Am J Transplant 2020;20:739-51. [PMID: 31652392 DOI: 10.1111/ajt.15664] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
33 Connolly JC, Lim JK. Non-invasive Fibrosis Assessment of Patients with Hepatitis C: Application of Society Guidelines to Clinical Practice. Curr Hepatology Rep 2019;18:249-58. [DOI: 10.1007/s11901-019-00471-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
34 Nabulsi NA, Martin MT, Sharp LK, Koren DE, Teply R, Zuckerman A, Lee TA. Predicting Treatment Failure for Initiators of Hepatitis C Virus Treatment in the era of Direct-Acting Antiviral Therapy. Front Pharmacol 2020;11:551500. [PMID: 33364936 DOI: 10.3389/fphar.2020.551500] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Gutkind S, Starbird LE, Murphy SM, Teixeira PA, Gooden LK, Matheson T, Feaster DJ, Jain MK, Masson CL, Perlman DC, Del Rio C, Metsch LR, Schackman BR. Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs. Drug and Alcohol Dependence 2022;232:109265. [DOI: 10.1016/j.drugalcdep.2022.109265] [Reference Citation Analysis]
36 Behzadifar M, Gorji HA, Rezapour A, Behzadifar M, Bragazzi NL. The role of insurance providers in supporting treatment and management of hepatitis C patients. BMC Health Serv Res 2019;19:25. [PMID: 30630488 DOI: 10.1186/s12913-019-3869-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
37 Brooks KM, Castillo-Mancilla JR, Morrow M, MaWhinney S, Rowan SE, Wyles D, Blum J, Huntley R, Salah LM, Tehrani A, Bushman LR, Anderson PL, Kiser JJ. Adherence to Direct-Acting Antiviral Therapy in People Actively Using Drugs and Alcohol: The INCLUD Study. Open Forum Infect Dis 2021;8:ofaa564. [PMID: 33447634 DOI: 10.1093/ofid/ofaa564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
38 Benitez TM, Fernando SM, Amini C, Saab S. Geographically Focused Collocated Hepatitis C Screening and Treatment in Los Angeles's Skid Row. Dig Dis Sci 2020;65:3023-31. [PMID: 31974916 DOI: 10.1007/s10620-020-06073-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
39 Haley DF, Edmonds A, Ramirez C, French AL, Tien P, Thio CL, Witt MD, Seaberg EC, Plankey MW, Cohen MH, Adimora AA. Direct-Acting Antiviral Hepatitis C Treatment Cascade and Barriers to Treatment Initiation Among US Men and Women With and Without HIV. J Infect Dis 2021;223:2136-44. [PMID: 33141170 DOI: 10.1093/infdis/jiaa686] [Reference Citation Analysis]
40 van Boemmel-Wegmann S, Lo Re V 3rd, Park H. Early Treatment Uptake and Cost Burden of Hepatitis C Therapies Among Newly Diagnosed Hepatitis C Patients with a Particular Focus on HIV Coinfection. Dig Dis Sci 2020;65:3159-74. [PMID: 31938995 DOI: 10.1007/s10620-019-06037-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Lau AA, Strebe JK, Sura TV, Hansen LA, Jain MK. Predictors of linkage to hepatitis C virus care among people living with HIV with hepatitis C infection and the impact of loss to HIV follow‐up. Health Science Reports 2022;5. [DOI: 10.1002/hsr2.645] [Reference Citation Analysis]
42 Saine ME, Moore TM, Szymczak JE, Bamford LP, Barg FK, Mitra N, Schnittker J, Holmes JH, Lo Re V 3rd. Validation of a modified Berger HIV stigma scale for use among patients with hepatitis C virus (HCV) infection. PLoS One 2020;15:e0228471. [PMID: 32023310 DOI: 10.1371/journal.pone.0228471] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
43 Simoncini GM, Hou Q, Carlson K, Buchacz K, Tedaldi E, Palella F , Jr, Durham M, Li J; HIV Outpatient Study (HOPS) Investigators. Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010-2018. AIDS Patient Care STDS 2021;35:392-400. [PMID: 34623891 DOI: 10.1089/apc.2021.0087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Seaman A, King CA, Kaser T, Geduldig A, Ronan W, Cook R, Chan B, Levander XA, Priest KC, Korthuis PT. A hepatitis C elimination model in healthcare for the homeless organization: A novel reflexive laboratory algorithm and equity assessment. Int J Drug Policy 2021;:103359. [PMID: 34325969 DOI: 10.1016/j.drugpo.2021.103359] [Reference Citation Analysis]
45 Du P, Wang X, Kong L, Jung J. Can Telementoring Reduce Urban-Rural Disparities in Utilization of Direct-Acting Antiviral Agents? Telemed J E Health. 2021;27:488-494. [PMID: 32882154 DOI: 10.1089/tmj.2020.0090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
46 Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2:100067. [PMID: 32118201 DOI: 10.1016/j.jhepr.2020.100067] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 23.5] [Reference Citation Analysis]
47 Breskin A, Westreich D, Hurt CB, Cole SR, Hudgens MG, Seaberg EC, Thio CL, Tien PC, Adimora AA. The Effects of Hepatitis C Treatment Eligibility Criteria on All-cause Mortality Among People With Human Immunodeficiency Virus. Clin Infect Dis 2019;69:1613-20. [PMID: 30615096 DOI: 10.1093/cid/ciz008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]